Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONTROL NETS: PRRT + CAPTEM in Neuroendocrine Tumors
NCT02358356Phase 2Completed
- Sponsor
- Australasian Gastro-Intestinal Trials Group
- Start
- Nov 2015
- Primary completion
- Oct 2021
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of lutetium Lu 177 dotatate, capecitabine, temozolomide in Pancreatic neuroendocrine tumor (PanNET), midgut neuroendocrine tumor (MNET), sponsored by Australasian Gastro-Intestinal Trials Group. Started Nov 2015; status: completed.
02
Drugs
lutetium Lu 177 dotatatecapecitabinetemozolomide
03
Conditions
Pancreatic neuroendocrine tumor (PanNET)midgut neuroendocrine tumor (MNET)
Beyond the preview
Go deeper on NCT02358356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02358356.